skip to main content

JVM-2

JVM-2

Catalogue No.

96090515

Cell Line Name

JVM-2

Cell Line Description

JVM-2 has been derived from EBV and TPA treated mononuclear cells from a 63 year old female patient with B-prolymphocytic leukaemia. Thirty-three percent of cells were shown to be positive for surface lambda light chain, 37% for IgA, 29% for IgG and 3% for IgM and IgD. In addition, 50% were found to express cytoplasmic IgM and lambda light chain. Expression of the following leukocyte differentiation antigens was found: CD9, CD19, CD20, CD23, CD24, MA6, CD37, CD38, FMC1, FMC7, MHC Class I, FMC16, MHC Class II DR/DP/DQ. The immunoglobulin heavy-and light-chain genes showed the same pattern of rearrangement as in the original prolymphocytes. The cells are lymphoblastoid with large floating aggregates present. The cell line has been eradicated from mycoplasma at ECACC.

Characteristics

Tissue of Origin

Blood

Morphology

Round

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 11
D5S818: 11,12
D7S820: 10,11
D13S317: 11,13
D16S539: 12,13
TH01: 6,9
TPOX: 8,11
vWA: 17

Karyotype

46,XX,-8,+t(3;8)(p12-13;q12),t(11;14)(q13;q32)

Applications

Ig expression of neoplastic cells

Disease

Lymphoma

Culture Conditions

Cell Type

Lymphoblastoid

Subculture Routine

Maintain cultures between 3-9 x 100,000/ml; 5% CO₂; 37°C.

Culture Medium

RPMI 1640 +2mM Glutamine + 10% Foetal Bovine Serum (FBS).

Growth Mode

Suspension

Additional Info

Depositor

Dr. J.V. Melo, Department of Haematology, Hammersmith Hospital, London

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Int. J. Cancer 1986;38:531, Clin Exp Immunol. 1988;73:23, Oncogene 1988; 3:99, Pathology 1988;20:10, Leuk Lymphoma 1992; 7:497

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: JVM-2 (ECACC 96090515).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.